Blockbuster cracks new market

 Posted 4 June 2025 AM

The TGA has expanded use of Lilly's blockbuster drug Mounjaro to treat moderate-to-severe obstructive sleep apnoea in adults - marking the first and only medicine to treat the common sleep disorder.

Already indicated for the management of type 2 diabetes and obesity, Mounjaro’s role in the treatment of obstructive sleep apnoea is by virtue of weight reduction, easing pressure on the chest and abdomen and reducing excess fat around the neck and throat.

To see the whole article, please login